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DCIS = ductal carcinoma in situ.
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Abstract
There is a delicate balance between the favourable and unfavourable
side-effects of screening in general. Overdiagnosis, the detection
of breast cancers by screening that would otherwise never have
been clinically diagnosed but are now consequently treated, is
such an unfavourable side effect. To correctly model the natural
history of breast cancer, one has to estimate mean durations of the
different pre-clinical phases, transition probabilities to clinical
cancer stages, and sensitivity of the applied test based on
observed screen and clinical data. The Dutch data clearly show an
increase in screen-detected cases in the 50 to 74 year old age
group since the introduction of screening, and a decline in
incidence around age 80 years. We had estimated that 3% of total
incidence would otherwise not have been diagnosed clinically. This
magnitude is no reason not to offer screening for women aged 50
to 74 years. The increases in ductal carcinoma in situ (DCIS) are
primarily due to mammography screening, but DCIS still remains a
relatively small proportion of the total breast cancer problem.
Introduction
Breast cancer screening has been effective in reducing
breast cancer mortality. Both randomised controlled trials and
nation-wide screening programmes have shown a roughly
25% reduction in disease-specific mortality for women aged
50 years and over invited to screening [1-4]. This benefit
applies to the group as a whole, but at the individual level it is
impossible to determine who will actually benefit or who will
receive more harm than benefit from such a programme:
there is a delicate balance between the favourable and
unfavourable side-effects of screening in general [5]. For
example, detecting breast cancers by screening that would
otherwise never have been clinically diagnosed, but are now
treated, is such an unfavourable side effect. Because of lead
time and length-biased sampling, the screening test will
generally detect more early lesions with possibly different
biological behaviour and also more slowly growing tumours,
especially ductal carcinoma in situ (DCIS). Screening at older
ages will, due to existing co-morbidity, lead to the detection
of clinically relevant diseases; however, women may not
necessarily benefit because they more often die due to other
diseases.
This paper presents quantitative estimates of overdiagnosis in
breast cancer screening based on microsimulation modelling,
with special emphasis on DCIS. In this study, overdiagnosis
is defined as diagnosing cancers that would not have been
diagnosed clinically if there were no screening programme.
Observations
Starting to screen a population systematically for breast
cancer will lead to the detection of cancers about three to
four years earlier than without such an approach [6];
therefore, the number of detected cancers at the population
level is expected to increase. Because screening is continued
every consecutive year, this number is higher, and remains so,
than if there were no systematic screening. Figure 1 shows
the Dutch national data since 1989, when screening was
gradually being implemented [7,8]. For women aged 50 to
69 years, implementation took place in the period 1990 to
1997. After an initial increase of around 30%, incidence in
the 50 to 69 year old age group stabilized at 16% higher than
without screening. Furthermore, the last years of screening
have resulted in an additional 10% increase, probably due to
more referrals and better screening performance. From 1999
onwards in the Netherlands women aged 70 to 74 were also
invited for screening. Compared to the year 1989, the
number of breast cancers diagnosed each year has
increased by 40%. Proportionally, this increase is largest for
DCIS. Figure 2a,b shows the increase in Dutch hospital
admissions for non-invasive breast cancer in the years 1990
to 1992 (at the start of nation-wide screening) in
municipalities that had started screening compared to
municipalities that had not; in the age group invited for
screening (at that time 50 to 69 year olds), the increase was
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3 to 5-fold (Fig. 2a). Strikingly, there was also an increase
outside the screening municipalities (Fig. 2b). Non-invasive
breast cancer, however, still accounted for only 4% of the
total incidence [8].
Modelling
These increases in incidence represent real overdiagnosis to
only a limited extent. From the observed rates, one can not
easily determine to what extent overdiagnosis is involved
because screening is still being continued. In these
circumstances, modelling of the natural history of breast
cancer and its early lesions, and what screening is estimated
to depict, is crucial and provides a ‘best guess’. Using the
microsimulation model MISCAN [6,9], we first simulate
individual life histories for women in the absence of screening
and then assess how these histories would change as a
consequence of a screening programme. The natural history
is modelled as a progression from no breast cancer through
pre-clinical disease (DCIS, T1a, 1b, 1c, T2+) to clinical
disease (same stages). From a given pre-clinical state, a
cancer may be detected by screening or become clinically
apparent or, if undiagnosed, progress to the next pre-clinical
state. To correctly model this natural history of breast cancer
for women in a certain age group, one has to estimate mean
durations of the different pre-clinical phases, transition
probabilities, and sensitivity of the applied test [10]. Basically,
one therefore needs data from two sources: observed screen
and clinical data. These data include clinical incidence data
by age and stage in the situation without screening, data on
screen-detected cancers by stage, screening round (and
interval) and age, and corresponding clinical incidence data
when screening is being implemented [11]. Although the
observed data can often be explained by a small range of
parameters (e.g., a somewhat higher sensitivity and shorter
mean duration of the stage may also result in a good fit), by
having more detailed data from several screening rounds, by
screening different age groups and/or by using different
screening intervals, best parameters often fall into a smaller
range [12]. In the Netherlands, such detailed data have been
used: in the past using pilot data [6], and more recent data
from the annual monitoring by the National Evaluation Team
for Breast cancer screening [7].
The fit of the model to the breast cancer screening pilot data
[6,12], as well as to the Dutch nation-wide data [9], has been
reported as quite satisfactory.
We also used the MISCAN approach to analyse the results
of the Health Insurance Plan trial study. These comparisons
show the potential power of modelling: the parameter values
for the invariant part of the natural history of pre-clinical
breast cancer are indeed the same, whereas the increase in
the sensitivity reflects the improvement in mammography.
Taking the obvious differences between HIP and Nijmegen
(one of the two Dutch pilot studies) into account, the model
shows that there is a good correspondence between the
screening data from these studies. The findings about the
duration of pre-clinical disease and the sensitivity of
screening can be compared with results from other modelling
approaches. Day and colleagues [13] applied this model to
data from Utrecht (the other Dutch pilot study). The study
reports a good fit of the model (chi-square of 7.2 and 7
degrees of freedom) when assuming a sensitivity of 99% and
a mean duration of 2.8 years. It is not indicated exactly what
data from Utrecht were used, but it is clearly a less detailed
subset of the data than we used for testing model
assumptions. An adapted version of the Day and Walter
model was applied to the Nijmegen data [14]. In general, the
Figure 1
Age-specific incidence of breast cancer (invasive/non-invasive) from 1989 to 2002 in the Netherlands [7,8].Page 3 of 5
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estimated parameters are comparable to the values found
with the MISCAN approach presented here, especially
regarding the age-dependency of the estimated duration of
the preclinical stage. The reported average duration is
somewhat shorter, however, for example, 2.5 years in the 50
to 64 year old age group.
Data on the natural history at older ages have been very
limited, but are slowly emerging now that the Dutch
programme includes women aged 70 to 74 years [15]. Data
on the natural history of DCIS are scarce [16], but
parameters concerning the screen-detectable pre-clinical
period can be estimated, based on the aforementioned data.
In our first analyses, we have assumed that 10% of invasive
breast cancers are preceded by a screen-detectable DCIS
phase and that the chance of progressing to invasive cancer
or clinical DCIS is almost 90% in the long term. Recent data
from randomised treatment trials support a high progression
rate in the long term [17]. The observed screen data are then
consistent/compatible with a mammography sensitivity of
40% and a mean screen-detectable duration of 5 years.
Results on overdiagnosis
Figure 3a,b shows the model-estimated changes in breast
cancer incidence (by age) in the Netherlands in a programme
for women aged 50 to 74 years screened every 2 years
(assuming an 80% attendance rate), compared to no
screening. Incidence rises at the starting ages, because all
young women have (in principle) never been screened before,
which means that cancers are detected that have already
progressed over time through the pre-clinical stages.
Figure 3a,b also clearly depicts the true extent of over-
diagnosis. Because of the earlier detection, cancers that would
have surfaced at ages 75 to 85 years have now been detected
earlier; clinical incidence at these ages must, therefore, be
lower. In Fig. 3a,b, the difference between the left area (extra
cancers detected by screening) and the right area (less
cancers diagnosed clinically) represents overdiagnosis. We
had estimated this to be 3% of the total incidence, or 8% of
screen-detected cancers. The Dutch data clearly show the
decline in incidence at around age 80 years. The higher
incidence than expected by the model around ages 55 to
65 years in 2002 (as estimated before the Dutch programme
started) confirms the better screening performance in more
recent years. It also illustrates the difficulty of estimating
overdiagnosis in a situation where a nation-wide screening
programme is being implemented.
During the first years of screening, the increase in newly
diagnosed cases in the age group invited to screening will
not yet be reflected by a decrease in incidence at older ages
as these are different cohorts of women. In the later years of
screening, the increase in newly diagnosed cases and the
decrease in incidence should be at a steady state, although
this isn’t always the case, because of other changes in the
screening programme.
Figure 3b shows that the change in DCIS detection is
especially striking, although some lesions would have
progressed to an invasive disease (not shown in the figure).
The amount of overdiagnosis, the increase in primary surgery/
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Figure 2
Hospital admissions for non-invasive breast cancer in the early years (1990 to 1992) of screening. (a) Admissions in Dutch municipalities with
screening compared to those with no screening. (b) Admissions per calendar year in municipalities without screening.
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to be weighed against the favourable effects of screening:
about 750 breast cancer deaths prevented per year (16%),
reduction of treatments for advanced disease and its
consequences for quality of life, and 15 life-years gained if dying
from breast cancer has been prevented. We consider this to be
a very acceptable balance at the population level [18].
Conclusion
Overdiagnosis is inherent to screening. The crucial issue is
the extent to which it happens and what the consequences
are for the population involved. This then has to balance with
the favourable effects of screening in order to be able to
decide on an appropriate screening policy. In breast cancer
screening, overdiagnosis is not negligible but is relatively
limited. The increases in DCIS are primarily due to
mammography screening, but they remain a relatively small
proportion of the breast cancer problem. The screen data
observed in this study provide workable assumptions on the
natural history of DCIS and do not lead to a major difference
in conclusions regarding overdiagnosis. More and more
women with DCIS are being treated by breast conservation,
and in the Netherlands screen-detected DCIS is more often
treated by conservation than clinically diagnosed DCIS.
Categorisation of DCIS lesions into high risk versus low risk
lesions (by screening) is still urgently needed.
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